Clinical Trials on Foie gras

Total 5135 results

Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Pneumococcal Infections

United States, Puerto Rico, Thailand, Turkey
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) (PNEU-PLAN)

Pneumococcal Infections

Finland, Malaysia, Poland, Russian Federation, Thailand
Centre Hospitalier Universitaire de Besancon
University Hospital, Geneva; UMC Utrecht; University of Oxford; University Hospital... and other collaborators

Completed

Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities (MODERN)

Enterobacteriaceae Infections | Resistance Bacterial

France
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (PNEU-PATH)

Pneumococcal Infections

United States, Korea, Republic of, Spain, Taiwan
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

Pneumococcal Infections

United States
The University of Texas Health Science Center,...

Withdrawn

Randomized Clinical Trial of Standard FMT Treatments (FMT)

Clostridium Difficile
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety Study of NBP606 in Healthy Infants

Pneumococcal Infections

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Pneumococcal Infections
GlaxoSmithKline

Completed

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Infections, Streptococcal

Chile
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Poland, Philippines
Centre Hospitalier Universitaire de Saint Etienne

Completed

Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne (ColoStaph)

STAPHYLOCOCCAL INFECTIONS

France
GlaxoSmithKline

Completed

Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children

Infections, Streptococcal

Czechia
GlaxoSmithKline

Completed

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria

Infections, Streptococcal

Nigeria
GlaxoSmithKline

Completed

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

Infections, Streptococcal

Singapore, Malaysia
GlaxoSmithKline

Completed

Phase I Study of Colistin Methanesulfonate Sodium

Infections, Pseudomonas

Australia
Valneva Austria GmbH

Completed

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

Clostridium Difficile

Germany, United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

Infections, Staphylococcal

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Pneumococcal Reference Standard

Pneumococcal Infections

United States
GlaxoSmithKline

Completed

Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.

Infections, Streptococcal

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

Staphylococcal Infection

United States
Merck Sharp & Dohme LLC

Completed

V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)

Staphylococcal Infection
National Institute of Allergy and Infectious Diseases...

Completed

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Staphylococcal Infection

United States
Virginia Commonwealth University
Astellas Pharma Inc

Completed

The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus

Staphylococcus Aureus

United States
University Hospital, Limoges

Completed

Community-acquired Methicillin-Resistant Staphylococcus Aureus Carriage Among Athletes (PSARM-S)

Staphylococcus Aureus
Johns Hopkins Bloomberg School of Public Health
Centers for Disease Control and Prevention; Institute of Child Health; Thrasher... and other collaborators

Completed

Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage

Pneumococcal Infections

United States
Pfizer

Completed

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

Pneumococcal Infections

Sweden, United States, Germany
Hamilton Health Sciences Corporation
St. Joseph's Healthcare Hamilton; McMaster University

Completed

Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile

Clostridium Difficile

Canada
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Pneumococcal Infections

United States, Sweden
Johns Hopkins Bloomberg School of Public Health
Wyeth is now a wholly owned subsidiary of Pfizer; United States Agency for... and other collaborators

Completed

Mother's Gift Project

Pneumococcal Infections

Bangladesh
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

Pneumococcal Infections

India
Michael E. DeBakey VA Medical Center
Baylor College of Medicine

Completed

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

Staphylococcus Aureus

United States
University of Melbourne
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pneumococcal Vaccination of Fiji Infants

Pneumococcal Infections

Fiji
Nabi Biopharmaceuticals

Completed

StaphVAX Immunogenicity in Orthopedic Implant Patients

Staphylococcal Infections | Joint Prosthesis

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Safety and Local Tolerability of Prevenar in Indian Children

Pneumococcal Infections
GPN Vaccines

Recruiting

Extension Safety and Immunogenicity Study of GPNV-001

Pneumococcal Infections

Australia
Sinovac Life Sciences Co., Ltd.

Recruiting

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infections

China
Sheba Medical Center
The Israel Science Foundation

Recruiting

Mother to Newborn Transmission of Staphylococcus Aureus and Dynamics of S.Aureus Carriage During the First Years Life

Staphylococcus Aureus

Israel
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Safety and Immunogenicity of CJCV2 With and Without ALFQ

Campylobacter Infection

United States
University of Calgary
Canadian Institutes of Health Research (CIHR); Alberta Health services

Completed

C Difficile Near-patient Diagnostics

Clostridium Difficile

Canada
Pfizer

Terminated

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Pneumococcal Infections

United States
Pfizer

Completed

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

Pneumococcal Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Pneumococcal Infections

United States, Australia, Canada, Chile, New Zealand, Poland, Russian Federation
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company

Completed

Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients (ANTISTAPH)

Staphylococcus Aureus

France
Pfizer

Completed

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Pneumococcal Infections

United States
Rothman Institute Orthopaedics

Unknown

Probiotics Pilot Project

Staphylococcus Aureus

United States
Pfizer

Completed

A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.

Pneumococcal Infections

Japan
Telethon Kids Institute
Papua New Guinea Institute of Medical Research

Completed

PCV13 in Non-pregnant Papua New Guinean Women

Pneumococcal Infections

Papua New Guinea
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Pneumococcal Infections

United States, Canada, Denmark, Finland, Israel, Spain

Clinical Trials on Foie gras

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations